• BioLineRx disclosed new preclinical data on GLIX1 in glioblastoma, supporting its recently initiated Phase 1/2a trial in recurrent or progressive disease.
• Multiple animal studies showed GLIX1 produced a clear anti-tumor effect and improved outcomes, including in a model designed to reflect resistance to temozolomide, where temozolomide did not show benefit.
• The results are intended to inform dose selection for the Phase 2 portion of the study.
• The companies plan to present the data at one or more future medical conferences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605190700PR_NEWS_USPR_____LN62377) on May 19, 2026, and is solely responsible for the information contained therein.